NeuroStar vs CloudTMS: Market Leader vs Cloud-Native Comparison

NeuroStar is the market leader in TMS — more US clinics use it than any other system. CloudTMS is a newer entrant that built its platform from the ground up with cloud connectivity in mind. The question isn’t just which is better in theory, but which is actually available where you live and covered by your insurance.

What You’ll Learn

• The technical differences between Neuronetics’ NeuroStar and CloudTMS systems
• Which protocols each platform supports
• US clinic availability for both systems
• Insurance landscape and prior authorization differences
• Which system fits different clinical situations

Technical Platform Overview

NeuroStar uses a traditional figure-8 coil design, delivered through the Neuronetics platform. It’s the most extensively studied TMS system in the US, with the largest patient treatment database of any TMS manufacturer. Neuronetics has iterated the platform over years, adding theta burst and accelerated protocols.

CloudTMS is a newer platform built around a cloud-based management system. Their coils are also figure-8 designs, but the differentiating factor is the software layer — clinic workflow management, patient tracking, and protocol configuration are handled through a web-based dashboard rather than traditional embedded software.

The CloudTMS approach appeals to multi-location clinic groups and academic systems that want centralized data management. For a single-location private practice, the cloud features matter less.

Protocols Supported

NeuroStar supports:

• Standard high-frequency (10 Hz) left prefrontal stimulation
• Theta burst stimulation (iTBS) — 3-minute sessions
• Intermittent and continuous theta burst variants
• Accelerated protocols for compressed treatment courses

CloudTMS supports:

• Standard rTMS protocols
• Theta burst stimulation
• Paired associative stimulation protocols

Both platforms support the protocols with the strongest clinical evidence. NeuroStar has more published data specifically using its platform for theta burst — the Neuronetics trials contributed substantially to the THREE-D data. CloudTMS can deliver equivalent protocols but with less platform-specific trial data.

FDA Clearances

NeuroStar holds FDA clearances for:

• Major Depressive Disorder (treatment-resistant) — the original 2008 clearance
• Obsessive-Compulsive Disorder
• Smoking cessation

CloudTMS holds FDA clearance for:

• Major Depressive Disorder (treatment-resistant)

CloudTMS does not yet have an OCD-specific clearance. For OCD patients, NeuroStar has a clear advantage in terms of the labeled indication. This affects insurance coverage — the OCD clearance gives NeuroStar a specific billing code that CloudTMS doesn’t have.

US Availability

This is where the gap is widest. NeuroStar has been in the US market since 2008 and has the largest commercial footprint of any TMS company. Neuronetics reports over 1,000 active systems installed across the country.

CloudTMS is more common in Europe, where the company has stronger roots. In the US, adoption has been slower. CloudTMS systems are available at select clinics, but finding one near you requires searching specifically.

Use our clinic finder and filter by device type to see what’s available in your region.

Clinical Outcomes

For depression treatment in a head-to-head sense, both systems are effective. The figure-8 coil design is identical, and theta burst protocols are deliverable on both platforms. The critical variable is whether your clinic has one system or the other — clinical outcomes depend more on the treating physician’s expertise with TMS than on the specific hardware manufacturer.

The key data advantage goes to NeuroStar simply because more patients have been treated on it. Neuronetics has published extensively on real-world outcomes, and the FDA’s 2008 clearance was based on a large multicenter trial specifically for the NeuroStar system.

Insurance Coverage

NeuroStar’s insurance relationships are deep and established. Most major insurers have specific coverage policies for NeuroStar TMS. The prior authorization process is well-documented, and billing codes are clearly established.

CloudTMS works with insurers but the coverage landscape is less developed. Some insurers may require additional documentation for a system they have less experience with. The prior authorization process can be slightly more complicated, though not insurmountable.

If insurance coverage certainty matters to you, NeuroStar has the advantage simply because more insurers have processed more NeuroStar claims.

The Bottom Line

NeuroStar wins on availability, insurance coverage, and depth of clinical data. If you can find a nearby clinic using it, that’s likely your most straightforward path to TMS treatment.

CloudTMS is a capable system with modern software design, but the US install base is smaller and the OCD clearance gap is real. As the company grows in the US market, this may shift — but for 2026, NeuroStar remains the more accessible option for most patients.

Search for NeuroStar clinics or CloudTMS providers in your area to see what’s available near you.